AHA 2015

Apixaban Efficacy, Safety Evaluated in AF Patient on Multiple Concomitant Medications

By November 14, 2015

Older patients, females, and those with comorbidities were more likely to be on multiple medications.

Apixaban vs. Warfarin: Effects Compared in AF Patients With, Without PAD

By November 14, 2015

Researchers conducted a post hoc analysis of the ARISTOTLE trial which included patients with atrial fibrillation (AF) and a risk of stroke treated with either apixaban or warfarin for the prevention of stroke/ systemic embolism.

Isosorbide Mononitrate Did Not Up Exercise Tolerance in HF Patients

By November 14, 2015

Patients were randomized to either 6 weeks of placebo first followed by 6 weeks of isosorbide mononitrate or 6 weeks of isosorbide mononitrate followed by 6 weeks of placebo.

Efficacy of Vericiguat Studied in Chronic HF Patients

By November 14, 2015

Vericiguat an investigational oral sGC (soluble guanylate cyclase) stimulator.

Study Compares Safety, Efficacy of Pradaxa vs. Warfarin for Reducing Stroke, Major Bleeding Risk

By November 14, 2015

The new findings were based on data from a pooled analysis of two large U.S. commercial health insurance databases.

Study Provides Insight into Antithrombotic Tx Reintroduction After Dabigatran Reversal

November 13, 2015

Idarucizumab (Praxbind) was recently granted accelerated approval as a reversal agent for patients on Pradaxa during emergency situations.

Staying on Brilinta Tx Improves CV Outcomes, Study Finds

By November 13, 2015

The Food and Drug Administration (FDA) recently approved a new 60mg dosage strength for Brilinta to be used in patients with a history of MI beyond the first year.

New Data Support Sustained Antiplatelet Effects With Durlaza

By November 12, 2015

New Haven Pharmaceuticals announced new data that demonstrates Durlaza (aspirin) extended-release capsules provide sustained antiplatelet control for a full 24-hour period in high-risk patients.

Entresto Cuts Hospital Readmissions in HF Patients

By November 12, 2015

PARADIGM-HF study, which included 8,442-patients, is the largest clinical trial ever conducted in heart failure.

Jardiance Reduced CV Risk Regardless of Baseline HF Status

By November 12, 2015

Jardiance, a sodium-glucose co-transporter 2 inhibitor, is indicated as adjunct to diet and exercise to improve glycemic control in adults with T2D.

Benefits of Praluent Added to Standard-of-Care Presented

By November 12, 2015

Results showed that approximately 74% of patients reached their pre-specified LDL cholesterol targets within 8 weeks of adding Praluent to their standard-of-care.

Gender Disparity in Cardiologists' Salaries

November 12, 2015

Gender differences in compensation even after adjustment for measured characteristics

Andexanet Alfa Can Reverse Effect of Factor Xa Inhibitors

November 12, 2015

Reversal of anticoagulant activity of apixaban and rivaroxaban seen in older healthy participants

Infrequent Monitoring for Heart Failure Patients on MRAs

November 12, 2015

Low monitoring rates in clinical practice in patients initiating mineralocorticoid receptor antagonists

'Cash for Lower Cholesterol' Program May Work

November 12, 2015

Cooperation is key to program's success, but benefits are modest

Home-Cooked Meals Linked to Lower Type 2 Diabetes Risk

November 12, 2015

Researchers also found association with fewer sugar-sweetened beverages, lower weight

Just One Energy Drink May Cause Harmful Spike in Blood Pressure

November 12, 2015

Physicians may need to ask young adults about energy drink intake in emergency settings

Many Americans Suffering Silent MIs

November 12, 2015

Evidence of myocardial scarring often appearing on scans, even if no attack was reported

Many Patients Worried About Sex Post ICD Implantation

November 12, 2015

Both patient and partner need better counseling before leaving the hospital, researcher says

Women More Often Receive Suboptimal Post-MI Care

November 12, 2015

This could explain gender gap in survival, researchers say

Landmark Blood Pressure Study May Change Clinical Practice

November 12, 2015

Risk of CVD was lowered by 25 percent, while all-cause mortality risk was reduced 27 percent

Combo Tx Ups Benefits in Intermittent Claudication

November 11, 2015

Greater improvements in waking distances, quality of life with revascularization plus exercise.

Short, Intense Bouts of Exercise More Beneficial in T2DM

November 11, 2015

Research suggests brief but harder workouts may provide better blood glucose control.